Gustafsson Moa, Silva Vítor, Valeiro Carolina, Joaquim João, van Hunsel Florence, Matos Cristiano
Department of Pharmacology, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, 41390 Gothenburg, Sweden.
Unidade Local de Saúde de Coimbra, EPE, 3004-561 Coimbra, Portugal.
Pharmaceuticals (Basel). 2024 Jul 31;17(8):1009. doi: 10.3390/ph17081009.
Opioids are the strongest analgesics available and are crucial in the treatment of acute and chronic pain. The line between these critical medications and how they are used beyond standard therapeutics in cases such as abuse, misuse, and medication errors needs to be understood, as it affects their safety, efficacy, and manner of use. The aim of this systematic review was to identify what is known about the adverse events resulting from the abuse, misuse, and medication errors associated with opioid use. A systematic search was conducted in the PubMed, Scopus and, EBSCO databases to retrieve studies from the inception to December 2023 reporting abuse, misuse, and medication errors associated with medicinal opioid use. Two authors independently screened titles and abstracts and full text according to eligibility using Covidence software. Full articles were examined by two independent reviewers, and disagreements were resolved by a third reviewer. The risk of bias was assessed by the JBI's critical appraisal tools. A total of 934 articles were screened by their title and abstract. Then, 151 articles were selected for full text screening. Of these, 34 studies were eligible for inclusion in this review. The included studies varied significantly in their population sizes, ranging from 9 individuals to 298,433 patients, and encompassed a diverse demographic, including all ages and both sexes. The studies consistently reported a range of adverse events associated with opioid use. Fentanyl, morphine, oxycodone, tramadol, and hydrocodone were frequently implicated. The data heterogeneity in this field resulted in challenges in drawing conclusions. The review highlights that some opioids, particularly fentanyl, morphine, and oxycodone, are frequently associated with preventable adverse drug reactions, abuse, and medication errors, underscoring the need for robust preventative measures and ongoing research to mitigate opioid-related harm.
阿片类药物是现有的最强效镇痛药,在急性和慢性疼痛的治疗中至关重要。必须了解这些关键药物与它们在滥用、误用和用药错误等情况中超出标准治疗用途的使用方式之间的界限,因为这会影响它们的安全性、有效性和使用方式。本系统评价的目的是确定与阿片类药物使用相关的滥用、误用和用药错误所导致的不良事件的已知情况。在PubMed、Scopus和EBSCO数据库中进行了系统检索,以检索从起始到2023年12月报告与药用阿片类药物使用相关的滥用、误用和用药错误的研究。两名作者使用Covidence软件根据入选标准独立筛选标题、摘要和全文。全文由两名独立评审员审查,分歧由第三名评审员解决。偏倚风险由JBI的批判性评价工具评估。共筛选了934篇文章的标题和摘要。然后,选择151篇文章进行全文筛选。其中,34项研究符合纳入本评价的条件。纳入的研究在人群规模上差异很大,从9人到298,433名患者不等,涵盖了不同的人口统计学特征,包括所有年龄和性别。这些研究一致报告了一系列与阿片类药物使用相关的不良事件。芬太尼、吗啡、羟考酮、曲马多和氢可酮经常被牵涉其中。该领域的数据异质性导致得出结论存在挑战。该评价强调,一些阿片类药物,特别是芬太尼、吗啡和羟考酮,经常与可预防的药物不良反应、滥用和用药错误相关,凸显了采取有力预防措施和持续研究以减轻阿片类药物相关危害的必要性。